UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000036332
Receipt number R000041396
Scientific Title Ascorbic acid treatment for Charcot-Marie-Tooth disease type 1A
Date of disclosure of the study information 2019/03/28
Last modified on 2019/03/28 23:09:25

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Ascorbic acid treatment for Charcot-Marie-Tooth disease type 1A

Acronym

Ascorbic acid treatment for CMT1A

Scientific Title

Ascorbic acid treatment for Charcot-Marie-Tooth disease type 1A

Scientific Title:Acronym

Ascorbic acid treatment for CMT1A

Region

Japan


Condition

Condition

Charcot-Marie-Tooth diease type 1A

Classification by specialty

Pediatrics

Classification by malignancy

Others

Genomic information

YES


Objectives

Narrative objectives1

Inihibition of progressive muscle weakness

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Phase I


Assessment

Primary outcomes

Charcot-Marie-Tooth disease neurological score will be used for primary outcome every 24 weeks after ascorbic acid treatment

Key secondary outcomes

Electrophysiological examination including latency, conduction velocity, temporal dispersion and compund muscle action potential.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Ascorbic acid treatment: 20mg/kg/day, dayly

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

1 years-old <

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Genetically Confirmed PMP duplication
2. Normal blood examination
3. Normal urinary analysis
4. Informed consent obtained

Key exclusion criteria

1. Unsuitable patient judged by the medical doctor

Target sample size

10


Research contact person

Name of lead principal investigator

1st name Katsunori
Middle name
Last name Fujii

Organization

Chiba University Graduate School of Medicine

Division name

Department of Pediatrics

Zip code

260-8670

Address

1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba, Japan

TEL

043-226-2144

Email

kfujii@faculty.chiba-u.jp


Public contact

Name of contact person

1st name Reiko
Middle name
Last name Aoyagi

Organization

Chiba University Hospital

Division name

Department of Clinical Investigation

Zip code

260-8670

Address

1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba, Japan

TEL

043-222-7171

Homepage URL


Email

prc-jim@chiba-u.jp


Sponsor or person

Institute

Chiba University

Institute

Department

Personal name



Funding Source

Organization

Chiba University

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Chiba University

Address

1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba, Japan

Tel

043-222-7171

Email

prc-jim@chiba-u.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 03 Month 28 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2019 Year 03 Month 28 Day

Date of IRB


Anticipated trial start date

2019 Year 06 Month 15 Day

Last follow-up date

2034 Year 06 Month 14 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 03 Month 28 Day

Last modified on

2019 Year 03 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041396


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name